Image Source: AsiaOne
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology Potential Companion Diagnostic to Monopar’s uPRIT Program GlobeNewswire August 12, 2020 WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus unlikely to progress to severe respiratory failure. The test would use Monopar’s proprietary monoclonal antibody, ATN-658, to detect soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patient plasma. A suPAR test for COVID-19 patients, if successful, could identify those at high risk for severe respiratory failure, facilitating earlier therapeutic interventions or allowing for the staging of patients to an optimal treatment based on their disease characteristics.
Source: AsiaOne